Logo Logo
Switch Language to German

Vogt, A. (2016): Lipoproteinapherese. Indikationen, Durchführung und Perspektive. In: Kardiologe, Vol. 10, No. 3: pp. 187-196

Full text not available from 'Open Access LMU'.


Hypercholesterolemia is a risk factor for cardiovascular diseases, which are still the most common cause of death in western countries. Since the introduction of statins the incidence of cardiovascular events has been reduced. For high risk patients in addition to lipid lowering medication, lipoprotein apheresis is available as a last resort therapy in Germany: in homozygous familial hypercholesterolemia (hoFH), in hypercholesterolemia if low-density lipoprotein cholesterol (LDLC) cannot be lowered to the target level and if lipoprotein(a) is elevated and LDL-C is at target level but the cardiovascular disease is progressive. Apheresis is safe, very well tolerated and significantly reduces cardiovascular events. For lowering lipoprotein(a), for which no medicinal therapy is so far available and for hoFH, apheresis still plays an important role.

Actions (login required)

View Item View Item